The retinoblastoma protein plays a critical role in regulating the G1/S transition. Less is known about the function and regulation of the homologous pocket protein p107. Here we present evidence for the posttranslational regulation of p107 by the Ca 2+ -activated protease calpain. Three negative growth regulators, the HMG-CoA reductase inhibitor lovastatin, the antimetabolite 5-¯uorouracil, and the cyclic nucleotide dibutyryl cAMP were found to induce cell typespeci®c loss of p107 protein which was reversible by the calpain inhibitor leucyl-leucyl-norleucinal but not by the serine protease inhibitor phenylmethylsulfonyl¯uoride, caspase inhibitors, or lactacystin, a speci®c inhibitor of the 26S proteasome. Puri®ed calpain induced Ca 2+ -dependent p107 degradation in cell lysates. Transient expression of the speci®c calpain inhibitor calpastatin blocked the loss of p107 protein in lovastatin-treated cells, and the half-life of p107 was markedly lengthened in lovastatian-treated cells stably transfected with a calpastatin expression vector versus cells transfected with vector alone. The data presented here demonstrate downregulation of p107 protein in response to various antiproliferative signals, and implicate calpain in p107 posttranslational regulation.
Introduction
The retinoblastoma (RB) family consists of RB, the product of the retinoblastoma susceptibility gene, and the related proteins p107 and p130 (Weinberg, 1995; Sidle et al., 1996) . RB plays a critical role in regulating G1/S cell cycle progression, and inactivation of RB has been implicated in the pathogenesis of various malignant neoplasms, including retinoblastoma, osteoblastic sarcoma and small cell lung cancer (Weinberg, 1995; Friend et al., 1987; Harbour et al., 1988) . RB and p107 are structurally and functionally related (Ewen et al., 1991; Zhu et al., 1993; Mayol et al., 1993; Whyte, 1995) . Both RB and p107 associate with cyclins, and they associate with and negatively regulate members of the E2F family of transcription factors (Lees et al., 1992; Kato et al., 1993) . RB and p107 are phosphorylated as cells progress through G1 into S phase, and phosphorylation abrogates E2F binding of both proteins. Transient expression of either RB or p107 has been shown to induce G1 arrest in several tumor cell lines (Qin et al., 1992; Zhu et al., 1993) . The cDNA tumor virus oncoproteins SV40 large T antigen, adenovirus E1A, and human papilloma virus E7, bind to both RB and p107 through a conserved sequence, the LXCXE domain (Dyson et al., 1989; Ewen et al., 1989; Stubdal et al., 1996 Stubdal et al., , 1997 Knudsen and Wang, 1998; Zalvide et al., 1998) . These viral oncoproteins disrupt the RB-E2F and the p107-E2F complexes, resulting in constitutive E2F activity and deregulation of cell growth (Bagchi et al., 1990; Weintraub et al., 1992; Knudsen and Wang, 1998) .
Despite many structural and functional similarities, it is not known whether RB and p107 are subject to the same mechanisms of transcriptional and posttranscriptional regulation. Cell cycle progression is tightly regulated and is associated with the sequential activation and inactivation of a series of cell cycle regulatory proteins. It has been shown that the levels of p107¯uctuate during the cell cycle. p107 levels are low in G0 and early G1, and then rise as cells approach the G1/S transition (Whyte, 1995; Moberg et al., 1996) . An important determinant of cell cycle protein periodicity is protein stability, and ubiquitin-dependent proteolysis, catalyzed by the 26S proteasome, has been implicated in the posttranslational regulation of a wide range of cell cycle regulatory proteins including cyclins B1, A, D1, and E, p53, p27, YY1, c-Jun, c-fos and c-myc (Glotzer et al., 1991; Ciechanover et al., 1991; Treier et al., 1994; King et al., 1995; Sudakin et al., 1995; Pagano et al., 1995; Crook et al., 1996; Clurman et al., 1996; Maki et al., 1996; Choi et al., 1997; Walowitz et al., 1998) .
Recently several studies have described proteolysis of RB. It has been reported that RB is a substrate for ubiquitin-targeted degradation in mammary epithelial cells immortalized by human papilloma virus-16 E7 protein and in normal mammary epithelial cells (Boyer et al., 1996; . It has been shown that RB is degraded by caspase protease in cells undergoing apoptosis in response to various stimuli (Janicke et al., 1996) , and, similarly, that RB is a substrate for a CED3-like protease during Fas-induced and DNA damage-induced apoptosis (Chen et al., 1997) . In contrast, the proteases regulating degradation of p107 are not known. In this study we examine a number of dierent settings in which p107 protein levels markedly decline and present evidence for the posttranslational regulation of p107 by the Ca 2+ -activated cysteine protease calpain.
Results

Lovastatin induces a marked decrease in p107 protein
Lovastatin is an inhibitor of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, an enzyme required for the conversion of HMG-CoA to mevalonic acid in the pathway leading to cholesterol synthesis (Alberts et al., 1980) , that has been used to induce a reversible G1 arrest in a variety of cell types (Keyomarsi et al., 1991) . We examined the eect of lovastatin on p107 and observed the level of p107 protein was signi®cantly decreased in CHP-100 cells exposed to 3 mM lovastatin for 36 h (Figure 1a ). The eect of lovastatin on p107 did not re¯ect general proteolysis, because there was no change in the level of other cell cycle regulatory proteins including cyclindependent kinase (Cdk) 2, Cdk4, or cyclin E ( Figure  1b ). Therefore we used lovastatin as a tool to examine the mechanisms governing the proteolysis of p107.
LLnL blocks lovastatin-induced p107 loss
As a ®rst approach to identifying the protease responsible for p107 catalysis we compared the level of p107 protein in CHP-100 (Figure 2a and c) , and PC-3-M cells ( Figure 2b ) treated with lovastatin for 36 h versus the level in cells incubated with lovastatin for 36 h to which various protease inhibitors were added to the culture medium for the ®nal 12 h. Incubation with the calpain inhibitor LLnL reversed the loss of p107 protein. LLnL also inhibits the activity of the 26 S proteasome, which has been implicated in the proteolysis of numerous cell cycle regulatory proteins (Rock et al., 1994) . Therefore we tested whether the Streptomyces metabolite lactacystin, a speci®c proteasome inhibitor (Fenteany et al., 1995) , reversed the loss of p107 protein. As shown in Figure 2 lactacystin had no detectable eect on the p107 protein level. The serine protease inhibitor PMSF also did not reverse the p107 protein loss (Figure 2b ). Flow cytometric analysis demonstrated that lovastatin induced an increase in the per cent of cells in G1 from 53 to 72%, and from 55 to 79% in CHP-100 and PC-3-M respectively. In cells treated with lovastatin plus LLnL, 74% of CHP-100 and 82% of PC-3-M cells were in G1. Thus the reversal of p107 down-regulation was not attributable to LLnLinduced reversal of G1 arrest.
LLnL and lactacystin block lovastatin-induced RB loss RB has been shown to be degraded by the ubiquitinproteasome pathway in some circumstances (Boyer et al., 1996) . There was a signi®cant decrease in the level of RB in CHP-100 cells after 36 h incubation with lovastatin which was reversible by co-culture with LLnL or lactacystin (Figure 2a ). Recovery by Figure 1 Eect of lovastatin on p107, Cdk2, Cdk4 and cyclin E levels. p107 (a), Cdk2, Cdk4 and cyclin E (b) protein levels were examined in untreated CHP-100 cells (lane 1) and in CHP-100 cells treated with 3 mM lovastatin (lanes 2 ± 5) and harvested at the time indicated. Equal amounts of cell lysate (50 mg protein) were resolved by SDS ± PAGE and subjected to Western blot analysis using polyclonal anti-p107, Cdk2, Cdk4, or cyclin E antibody and chemiluminescence detection Figure 2 Eect of LLnL and lactacystin treatment on the levels of p107, pRB and cyclin B1 protein in CHP-100 cells (a and c) and PC-3-M cells (b). (a) Untreated control cells were compared to cells treated with lovastatin (3 mM) for 36 h, LLnL (100 mM) for 12 h, lactacystin (10 mM) for 12 h, or lovastatin 36 h plus LLnL for the ®nal 12 h or lovastatin 36 h plus lactacystin for the ®nal 12 h. Western blot analysis was performed using polyclonal antibody to p107 and pRB. (b) Lanes 1 ± 6 were treated as described in (a). The cells in lane 7 were treated with PMSF (100 mM) for 12 h, and cells in lane 8 received lovastatin for 36 h and PMSF for the ®nal 12 h. Western blot analysis was performed using polyclonal antibody to p107. (c) The cells were treated as described in (a). Western blot analysis was performed using polyclonal antibody to p107 and monoclonal anti-cyclin B1 antibody lactacystin is compatible with previous data showing degradation of RB by the proteasome . These data imply that within the same cell, and in response to the same stimulus, the pathway of p107 degradation may dier from the pathway for RB degradation.
Lactacystin prevents the degradation of cyclin B1
Cyclin B1 was one of the ®rst proteins shown to be regulated by ubiquitination and subsequent proteasome-mediated degradation (Glotzer et al., 1991) . There was a marked decline in the level of cyclin B1 protein in lovastatin-treated CHP-100 cells, which was completely reversible by the proteasome inhibitor lactacystin (Figure 2c ). These data indicate that the lack of reversal of lovastatin-induced p107 loss by lactacystin was not due to the failure of lactacystin to act in CHP-100 cells. These data are consistent with previous reports showing that cyclin B1 degradation is through the proteasome, and further support a calpainmediated, non-proteasomal degradation mechanism for regulation of p107.
Lack of eect of caspase inhibitors on p107 levels
Recent studies have shown the existence of a family of cysteine proteases, related to the C. elegans death gene ced-3, which are activated during the induction of apoptosis (Kumar and Harvey, 1995; Nicholson et al., 1995; Henkart, 1996) . This caspase family of proteases can be selectively inhibited by synthetic cleavage-sitedirected FMK-modi®ed peptide inhibitors (Sarin et al., 1996) . We investigated the eect of the active inhibitors ZVAD-FMK and BD-FMK, and the inactive peptidyl analog ZFA-FMK on p107 levels in control and lovastatin-treated CHP-100 cells ( Figure 3 ). Cells were incubated with or without lovastatin for 36 h, and, where indicated, peptidyl analogs were added to the culture dishes for the last 12 h of incubation. Total cell lysates were prepared and p107 levels were examined by Western blot analysis. The level of p107 protein in CHP-100 cells treated with the caspase inhibitors was similar to control cells. Furthermore, these protease inhibitors did not block the lovastatin-induced loss of p107.
These data further indicate that the proteolysis of p107 in these cell cultures is speci®cally calpainassociated.
Increase in p107 half-life in response to LLnL
If p107 protein is degraded by calpain in vivo, then calpain inhibition in vivo would be expected to stabilize p107 protein. To test this we determined the half-life of p107 protein in the presence or absence of LLnL in lovastatin-treated CHP-100 and PC-3-M cells. Cells incubated with lovastatin for 36 h were treated with or without LLnL for the last 12 h. After 36 h cycloheximide was added and the cells were harvested at the times indicated. In both cell lines, the p107 half-life was shortened by lovastatin treatment (Figure 4 ). In contrast, in the presence of LLnL the half-life of p107 protein was substantially returned to control levels.
Reversal of 5-FU-induced p107 degradation by LLnL
A variety of agents that induce growth arrest or apoptosis, including classical cytotoxic drugs, were tested to identify another agent that induced p107 proteolysis. The antimetabolite 5-FU was found to markedly lower the level of p107 in the human breast cancer cell line MCF-7 ( Figure 5 ). MCF-7 cells were incubated with 5-FU for 48 h with or without LLnL or lactacystin for the last 12 h. LLnL reduced the loss of p107 protein. In contrast, in the presence of lactacystin p107 protein was not signi®cantly recovered.
LLnL reverses loss of p107 induced by dibutyryl cAMP cAMP has been shown to induce growth arrest in cells of epithelial origin (Bang et al., 1994; Tortora et al., 1994) . Therefore we tested the eect of cell permeant cyclic AMP analogs on p107 protein levels. As shown were incubated in the presence or absence of lovastatin where indicated. LLnL (100 mM) was added for the ®nal 12 h. Cycloheximide (100 mg/ml) was added for the time indicated, and the level of p107 protein was determined by Western blot analysis in Figure 6 , dibutyryl cAMP induced marked downregulation of p107 protein in MCF-7 breast carcinoma cells. Kinetic analysis demonstrated that loss of p107 was associated with a marked shortening of the p107 protein half-life, and that the reversal of p107 protein loss by LLnL was associated with normalization of the p107 half-life ( Figure 6 ). Dibutyryl cAMP and 5-FU induced modest increases in the per cent of cells in G1, and for both treatments addition of LLnL somewhat augmented the per cent of cells in G1, precluding reversal of p107 down-regulation due to reversal of G1 arrest (data not shown).
Degradatioan of p107 protein by puri®ed calpain
Calpain, or Ca 2+ -activated neutral protease, is an intracellular nonlysosomal cysteine protease that requires calcium ions for activity (Croall and Demartino, 1991) . The results presented above indicated that calpain may act as an endogenous regulator of p107. These data prompted us to determine if p107 acts as a substrate for puri®ed calpain in vitro. Cell lysates from untreated CHP-100 cells were incubated with puri®ed calpain under varying conditions and p107 levels were determined by Western blot analysis (Figure 7 ). In the presence of 1 mM CaCl 2 , calpain caused a complete loss of detectable p107, and, consistent with a calcium requirement for calpain-mediated p107 proteolysis, simultaneous incubation of cell lysate with calpain and the calcium chelator EGTA prevented the loss of p107 protein. Boiling calpain before addition abrogated the calpain-induced loss of p107.
Calpastatin reversed the loss of p107 in lovastatintreated cells Calpastatin is a highly speci®c endogenous protein inhibitor of intracellular calpain (Mohan and Nixon, 1995; Suzuki et al., 1987) . To further assess the role of calpain in p107 regulation in vivo we studied the eect of overexpressing calpastatin on p107 levels. PC-3-M cells were transiently transfectd with a calpastatin cDNA expression vector or with the vector alone, grown in the presence or absence of lovastatin, and p107 levels were determined by immunocytochemistry. Cells transiently transfected with calpastatin were cotransfected with a GFP expression vector. Cells were analysed for green¯uorescence, indicative of GFP expression, and red¯uorescence, which indicated p107 levels. All log phase PC-3-M cells expressed moderately high levels of p107 (Figure 8a ). After treatment with lovastatin, the level of p107 protein was uniformly reduced. In contrast, cells transiently transfectd with the calpastatin expression vector, as evaluated by GFP expression, had a markedly higher p107 level. CHP-100 cells stably transfected with the calpastatin expression vector were also generated. The level of calpastatin protein was elevated in these cells as compared to cells transfected with vector alone (Figure 8b) , and the constitutive level of p107 protein was also elevated in the calpastatin-transfected cells (Figure 8b ). The p107 half-life after treatment with lovastatin was substantially increased in CHP-100 cells stably transfected with the calpastatin expression vector, when compared to cells transfected with vector alone (Figure 8c ). These results further support a role for calpain in p107 proteolysis.
Discussion
Cell division is controlled by a carefully coordinated series of transcriptional and posttranscriptional events. Among posttranscriptional events phosphorylation and Figure 6 Eect of dibutyryl cAMP on the half-life of p107 protein in MCF-7 cells. MCF-7 cells were incubated in the absence or presence of dibutyryl cAMP as indicated for 48 h. LLnL (100 mM) was added for the ®nal 12 h. Cycloheximide (100 mg/ml) was added for the time indicated, and the level of p107 protein was determined by Western blot analysis Figure 7 In vitro degradation of p107 protein by puri®ed calpain. CHP-100 cell lysates were incubated for 45 min at 308C with buer alone (lane 1), with puri®ed calpain (lanes 3 and 4) or boiled-calpain (lane 2) in the presence of 1 mM CaCl 2 (lanes 1 ± 4) or in the presence of 10 mM EGTA (lane 4) proteolysis are particularly critical, and recent work has shown that proteolysis has a pervasive role in regulating cell cycle progression (King et al., 1996) . A number of recent reports have described posttranslational regulation of RB by either caspase or the proteasome (Janicke et al., 1996; Chen et al., 1997; . In contrast, the proteases responsible for degradation of p107 have not been described previously. In the experiments reported here we have identi®ed several stimuli that induce a substantial down-regulation of p107 protein, and we have used these agents to examine the mechanism of p107 proteolysis. The data presented here support a role for the cysteine protease calpain in the posttranslational regulation of p107 protein.
Calpain has been implicated in a wide range of normal physiologic events including platelet activation and apoptosis, and in a variety of pathologic states, including post-ischemic neurodegeneration, cataract formation, and Alzheimer's Disease (Croall and Demartino, 1991; Rami and Krieglstein, 1993; Saito et al., 1993; Saido et al., 1994) . Reported calpain substrates include cytokines, cytoskeletal-associated proteins, enzymes, including focal adhesion kinase (Cooray et al., 1996) and protein kinase C (Croall and Demartino, 1991; Eto et al., 1995) , and the transcriptional activators c-fos, c-Jun, YY1, and p53 (Hirai et al., 1991; Kavita and Mizel, 1995; Walowitz et al., 1998) .
As shown in Figure 1 , the down-regulation of p107 in lovastatin-treated cells was reversible by incubation of the intact cells with the calpain inhibitor LLnL. In addition to blocking calpain activity LLnL is an inhibitor of the 26S proteasome Rock et al., 1994) . Therefore we tested for the role of the ubiquitin-proteasome pathway in the degradation of p107. Lactacystin is a highly speci®c and irreversible inhibitor of the proteasome in vitro and in intact cells. It has not been found to block the activity of other proteases including calpain, cathespin B, chymotrysin, trypsin and papain (Fenteany et al., 1995) . We found that lactacystin signi®cnatly reversed the loss of cyclin B1, which has been shown to be degraded via the proteasome, but had no eect on the level of p107 (Figure 2 ). There was also no reversal by the serine protease inhibitor PMSF, nor was there reversal of p107 loss by the peptide aldehyde caspase inhibitors (Figure 3 ). These data implicated calpain in p107 proteolysis.
The endogenous protein calpastatin is a highly speci®c inhibitor of calpain activity (Suzuki et al., 1987; Mohan and Nixon, 1995) . Transient transfection experiments in which calpastatin protein was overexpressed demonstrated that calpastatin markedly reversed the loss of p107 protein in lovastatin-treated CHP-100 cells. We also derived CHP-100 cells stably transfected with the full-length calpastatin expression vector. The level of calpastatin in transfectants was sixfold higher than in non-transfected or vector alonetransfected cells, as determined by Western blot analysis using anti-calpastatin antibody (data not shown). The half-life of p107 was increased in the calpastatin-transfected cells, compared to the vectoralone transfected CHP-100 cells (Figure 8 ), further implicating calpain in the in vivo regulation of p107.
Although the data presented here demonstrate that p107 can be degraded by calpain in vitro, and that calpain inhibitors can regulate p107 degradation in vivo, the data do not demonstrate that p107 is a direct substrate of calpain. The cleavage site utilized by calpain is too variable to identify a consensus motif that would allow identi®cation of a characteristic calpain-catalyzed clip. Furthermore we have not observed fragments of p107 protein in the cell lysates studied (data not shown). Calpain has been shown to . Transfected cells were selected with G418. Western blot analysis for calpastatin protein expression using anti-calpastatin antibody was performed. In the same cell lysates, the level of p107 protein was also examined by Western blot analysis. (c) Cells were treated with 3 mM lovastatin for 36 h, cycloheximide (100 mg/ml) was added for the time indicated, and the level of p107 protein was determined by Western blot analysis catalyze limited cleavage of some substrates and extensive cleavage of other substrates, such as casein, which is hydrolyzed by calpain into acid-soluble peptides. Thus, in vivo, it is possible that p107 is directly degraded by calpain, that p107 is clipped by calpain and further degraded by other enzymes, or that p107 is degraded by an enzyme or enzymes that themselves are subject to regulation by calpain.
In contrast to the lack of eect of lactacystin on p107 levels, the data in Figure 1 demonstrate that lactacystin substantially reversed the down-regulation of RB in lovastatin-treated cells. These data suggest that RB and p107 can be targeted by dierent proteases. There are a number of important biological dierences between RB and p107. Although both p107 and RB inhibit the growth of sensitive cell types, there appear to be dierences in the mechanism of growth arrest (Zhu et al., 1993) . RB and p107 have been reported to inhibit the expression of dierent E2F-regulated genes (Hurford et al., 1997) . The phenotypes of Rb7/7 and p1077/7 mice are markedly dierent (Lee et al., 1996) . Mice that are heterozygous for RB develop pituitary tumors, but there is no increase in tumor incidence in mice heterozygous for p107. Loss or mutation of RB has been associated with a variety of tumor types, but there have not been any tumors yet detected with mutations in p107.
A growing list of proteins, including p53, c-fos, cjun, cyclin D1, N-myc, YY1, and NF-kB have been shown to be degraded by the proteasome pathway and by calpain (Hirai et al., 1991; Palombella et al., 1994; Treier et al., 1994; Pagano et al., 1995; Liu et al., 1996; Maki et al., 1996; Diehl et al., 1997; Choi et al., 1997; Gonen et al., 1997; Bonvini et al., 1998; Wakowitz et al., 1998) . The data presented in Figure 1 suggest that in the same cell, and in response to the same stimulus, RB was degraded through the proteasome, while the homologous protein p107 was degraded by calpain. This dierential targetting of RB and p107 may re¯ect structural dierences between the two proteins. Alternatively, in response to dierent stimuli these proteins may be subject to degradation by either calpain or the proteasome. An example of this dual regulation was shown recently in myoblasts where the transcription factor YY1 was degraded by calpain during skeletal muscle cell dierentiation, and by the proteasome in response to serum starvation (Walowitz et al., 1998) . As discussed above, a considerable body of evidence has accumulated showing that RB and p107 function, although partially overlapping, may also be divergent. Recognition of RB and p107 by distinct intracellular proteases provides a potential posttranslational mechanism for rapid selective modulation of the intracellular levels of these homologous pocket proteins.
Materials and methods
Cell culture
The Ewing's sarcoma cell line CHP-100 was obtained from Dr A Evans, Children's Hospital of Philadelphia. PC-3-M cells, a human androgen-independent prostate carcinoma cell line, were a gift of Dr James Kozlowski, Department of Urology, Northwestern University Medical School. The human breast carcinoma cell line MCF-7 was obtained from the American Type Culture Collection. Cells were maintained as monolayer cultures in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum, penicillin, streptomycin and amphotericin (Bio¯uids, Gaithersburg, MD, USA). 
Reagents
Cell cycle analysis
Cells were ®xed in 70% ethanol, incubated with RNAse A and the DNA intercalating dye propidium iodide, and cell cycle phase analysis was performed by¯ow cytometry using a Becton Dickinson FACStar¯ow cytometer and Becton Dickinson Cell Fit software (San Jose, CA, USA).
Western blot analysis
Cells were washed in PBS (phosphate-buered saline) and lysed in TNN lysis buer [40 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40, 0.1 mM sodium orthovanadate, 2 mg/ml aprotinin, 2 mg/ml leupeptin and 100 mg/ml PMSF] at 48C for 20 min with occasional vortexing. Cell lysates were centrifuged at 14 000 r.p.m. for 15 min at 48C to remove cell debris. Equal amounts of protein were subjected to electrophoresis on 7.5% SDS ± polyacrylamide gels and transferred to nitrocellulose membranes (Schleicher & Schuell, Keene, NH, USA) by electroblotting. The blots were blocked, incubated with polyclonal anti-p107 antibody, washed with 10 mM Tris, pH 7.5, 50 mM NaCl and 2.5 mM EDTA, incubated with horseradish peroxidase-conjugated secondary antibody, and p107 protein was detected with an enhanced chemiluminescence detection system (Amersham). To determine the p107 protein half life, 60 ± 70% con¯uent cell cultures were treated with cycloheximide (100 mg/ml). At each time point indicated cells were washed with cold PBS, lysed in TNN buer and p107 levels were determined by Western blot analysis In vitro degradation of p107 protein by puri®ed calpain CHP-100 cells were lysed in 40 mM Tris HCl, pH 7.5, 120 mM NaCl. Puri®ed calpain (m-calpain, the 80 KD subunit of Ca 2+ -activated neutral protease from rabbit skeletal muscle, 1 unit per 33 mg protein) was incubated with 40 mg protein from cell lysate for 45 min at 308C. After incubation SDS sample buer was added, the samples were boiled, centrifuged, and the supernatant was run on a SDS±polyacrylamide gel, and protein was detected by Western blot analysis.
Transient transfection with calpastatin
PC-3-M cells were transfected using Lipofectamine (GIBCO/BRL, Grand Island, IL, USA) accordingn to the manufacturer's instructions. Cells were transfectd with 1.5 mg/ml calpastatin plasmid in pcDNA3 vector or pcDNA3 vector alone. For transient transfection experiments vector control and calpastatin-transfected cells were co-transfected with a GFP (green¯uorescent protein) expression vector (pEGFP, 1.5 mg/ml; Clontech, Palo Alto, CA, USA). For stable transfections CHP-100 cells were transfected as above and selected in 400 mg/ml G418 (GIBCO/BRL, Grand Island, IL, USA).
Cytochemical analysis of p107
PC-3-M cells were grown on sterile coverslips and transfected as described above. After 5 h the medium was changed from Optimem to RPMI 1640 containing 10% fetal bovine serum. After 15 h further incubation some of the dishes received 10 mM lovastatin, and the cultures were incubated for an additional 30 h. The cells were then ®xed with 3.7% formaldehyde in PBS for 10 min, and permeabilized with 0.2% Triton X-100 for 10 min at room temperature (Szekely et al., 1991) . Nonspeci®c binding sites were blocked by incubating the cells with 1% bovine serum albumin in PBS for 1 h at 48C. Rabbit polyclonal anti-p107 antibody was added to the coverslips and incubated for 1 h at 48C. The coverslips were washed two times for 2 min with PBS and incubated at 48C for 1 h with Texas Red-conjugated goat anti-rabbit immunoglobulin (Molecular Probes, Eugene, OR, USA). After incubation, the coverslips were washed with PBS, rinsed quickly with water, air-dried, mounted using SlowFade (Molecular Probes), and imaged using a Zeiss Axiophot microscope interfaced with a CCD camera (Optronics Engineering, Goleta, CA, USA).
